X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Alexa Fluor® 647 anti-mouse CD4 antibody

RRID:AB_389325

Antibody ID

AB_389325

Target Antigen

CD4 See NCBI gene mouse

Proper Citation

(BioLegend Cat# 100530, RRID:AB_389325)

Clonality

monoclonal antibody

Comments

Applications: FC, IF, IHC

Clone ID

Clone RM4-5

Host Organism

rat

Vendor

BioLegend Go To Vendor

Cat Num

100530

Publications that use this research resource

Small Interfering RNA-Mediated Control of Virus Replication in the CNS Is Therapeutic and Enables Natural Immunity to West Nile Virus.

  • Beloor J
  • Cell Host Microbe
  • 2018 Apr 11

Literature context:


Abstract:

No vaccines or therapeutics are licensed for West Nile virus (WNV), a mosquito-transmitted neuroencephalitic flavivirus. The small interfering RNA siFvEJW targets a conserved sequence within the WNV E protein and limits virus infection. Using a rabies virus-derived neuron-targeting peptide (RVG9R) and an intranasal route for delivering siFvEJW to the CNS, we demonstrate that treatment of WNV-infected mice at late stages of neuroinvasive disease results in recovery. Selectively targeting virus in the CNS lowers viral burdens in the brain, reduces neuropathology, and results in a 90% survival rate at 5-6 days post-infection (when viral titers peak in the CNS), while placebo-treated mice succumb by days 9-10. Importantly, CNS virus clearance is achieved by humoral and cell-mediated immune responses to WNV infection in peripheral tissues, which also engender sterilizing immunity against subsequent WNV infection. These results indicate that intranasal RVG9R-siRNA treatment offers efficient late-stage therapy and facilitates natural long-term immunity against neuroinvasive flaviviruses.

Funding information:
  • NHLBI NIH HHS - U01-HL66618(United States)